Aadi Bioscience, Inc.

NasdaqCM:AADI Stock Report

Market Cap: US$56.2m

Aadi Bioscience Management

Management criteria checks 2/4

Aadi Bioscience's CEO is Dave Lennon, appointed in Oct 2023, has a tenure of 1.08 years. total yearly compensation is $2.14M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.093% of the company’s shares, worth $52.14K. The average tenure of the management team and the board of directors is 2.4 years and 3.3 years respectively.

Key information

Dave Lennon

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage7.5%
CEO tenure1.1yrs
CEO ownership0.09%
Management average tenure2.4yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Jul 03
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Jul 02
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10
Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07
Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12
Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16
Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10
Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Sep 28
A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Sep 21

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Jul 06
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Jun 23

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27
What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

CEO Compensation Analysis

How has Dave Lennon's remuneration changed compared to Aadi Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$62m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$160k

-US$66m

Compensation vs Market: Dave's total compensation ($USD2.14M) is above average for companies of similar size in the US market ($USD652.28K).

Compensation vs Earnings: Insufficient data to compare Dave's compensation with company performance.

CEO

Dave Lennon (53 yo)

1.1yrs

Tenure

US$2,135,687

Compensation

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Leadership Team

NamePositionTenureCompensationOwnership
David Lennon
President1.1yrsUS$2.14m0.093%
$ 52.1k
Scott Giacobello
CFO, Treasurer3yrsUS$1.97m0%
$ 0
Stephen Rodin
Senior VP of Legal & General Counsel2.8yrsno datano data
Raymond Steitz
Senior VP of Human Resources & Chief Human Resources Officer2.4yrsno datano data
Bryan Ball
Chief Technical Operations Officer2.3yrsno data0.41%
$ 228.0k

2.4yrs

Average Tenure

54yo

Average Age

Experienced Management: AADI's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Lennon
President1.1yrsUS$2.14m0.093%
$ 52.1k
Caley Castelein
Independent Chairman of the Board3.3yrsUS$258.91k0.080%
$ 44.9k
Emma Reeve
Independent Director3.2yrsUS$240.91k0%
$ 0
Anupam Dalal
Independent Director3.3yrsUS$235.91k0.0046%
$ 2.6k
Karin Hehenberger
Independent Director3.3yrsUS$227.41k0%
$ 0
Richard Maroun
Independent Director7.8yrsUS$240.91k0%
$ 0
Mohammad Hirmand
Independent Director1.7yrsUS$345.60k0%
$ 0
Behzad Aghazadeh
Independent Director3.3yrsUS$225.41k0%
$ 0

3.3yrs

Average Tenure

53yo

Average Age

Experienced Board: AADI's board of directors are considered experienced (3.3 years average tenure).